Intranasal mRNA-lipid nanoparticle vaccines elicit significant protection against SARS-CoV-2 in hamsters biorxivpreprint moderna_tx mRNA LipidNanoparticle NanoparticleVaccine SARSCoV2 COVID19 Vaccine HamsterModel
By Dr. Chinta SidharthanJan 16 2023Reviewed by Aimee Molineux In a recent study posted to the bioRxiv* preprint server, researchers from the United States evaluated the efficacy and immunogenicity of an intranasal messenger ribonucleic acid -lipid nanoparticle vaccine against severe acute respiratory syndrome coronavirus 2 using a hamster model.
The current respiratory disease vaccines are administered through the intramuscular route, which largely induces systemic immunity and a lower level of mucosal immunity. Since most respiratory viruses enter through the mucosal route, intranasally administered vaccines that induce localized mucosal immunity and systemic immunity present the advantage of targeting the viruses at the site of entry, establishing protection, and limiting the infection early.
Enzyme-linked immunosorbent assay was used to determine the binding antibody levels of spike-specific serum immunoglobulin G or IgA. In contrast, the plaque reduction neutralization test was used to measure the serum-neutralizing antibody titers to evaluate the immunogenicity of the vaccine. Results The results indicated that the SARS-CoV-2 spike-specific IgA and IgG antibodies and the neutralizing antibody levels induced by the mRNA-LNP intranasal vaccine were comparable to those induced by the intramuscular vaccine. The antibody titers elicited by the mRNA-LNP2 vaccine were significantly higher than those induced by the mRNA-LNP1 vaccine. Furthermore, the IgA titers elicited by the mRNA-LNP2 vaccine at 25 μg dosage were higher than those induced by the intramuscular vaccine at 0.
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
Artemisia argyi plant extracts and phytochemicals shown to inhibit SARS-CoV-2 in new researchArtemisia argyi plant extracts and phytochemicals shown to inhibit SARS-CoV-2 in new research researchsquare UCSanDiego ArtemisiaArgyi SARSCoV2 COVID19 Coronavirus Phytochemicals
続きを読む »
Study investigates the spectrum of antibody immunity across several SARS-CoV-2 variantsStudy investigates the spectrum of antibody immunity across several SARS-CoV-2 variants medrxivpreprint UniofExeter antibody immunity protein spike SARSCoV2 covid coronavirus COVID19
続きを読む »
Researchers report on the largest cohort of patients tested using plasma mcfDNA sequencing for pathogen detectionResearchers report on the largest cohort of patients tested using plasma mcfDNA sequencing for pathogen detection medrxivpreprint CUBoulder MedicalCollege KariusInc DNAsequencing DNA pathogen disease
続きを読む »
What is the efficacy of the COVID-19 second booster versus the first booster and prior COVID-19 infections?What is the efficacy of the COVID-19 second booster versus the first booster and prior COVID-19 infections? medrxivpreprint SantePubliqueFr COVID19 Coronavirus SARSCoV2 COVIDInfection Booster SecondBooster
続きを読む »
The trajectory of CD4+ T cell responses to mRNA vaccines in older individualsThe trajectory of CD4+ T cell responses to mRNA vaccines in older individuals NatureAging KyotoU_News mRNA COVID19 coronavirus covid RNA cell Tcell aging agingresearch
続きを読む »
HRT could prevent Alzheimer's disease in at-risk women, study suggestsResearchers said hormone replacement therapy (HRT) is associated with better memory, cognitive function and larger brain volumes in later life in women carrying a gene considered the strongest risk factor for Alzheimer's disease.
続きを読む »